Observational studyMedicine2025
Association between asprosin and metabolic syndrome in people living with human immunodeficiency virus: A case-control study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The lifespan of people living with human immunodeficiency virus (PLWH) has been extended following antiretroviral therapy, which, paradoxically, has increased the burden of metabolic syndrome (MS). Asprosin has emerged as a novel biomarker strongly associated with MS and other metabolic indicators. This study aimed to investigate the relationship between serum asprosin levels and MS in PLWH. This prospective case-control study enrolled 111 PLWH with MS and 111 PLWH without MS as controls. A 1:1 propensity score matching was performed to adjust for potential confounding factors, including age and antiretroviral therapy regimen. Serum asprosin levels and other clinical variables were measured. PLWH with MS exhibited significantly higher serum asprosin levels compared to those without MS (19.2 [14.2-24.4] vs 15.4 [11.4-18.1] ng/mL, respectively, P < .001). Multivariate logistic regression analysis confirmed that elevated serum asprosin levels (odds ratios = 1.239, 95% confidence interval: 1.063-1.445, P = .006) were associated with MS in this population. Notably, the use of integrase strand transfer inhibitors was associated with the highest serum asprosin levels, followed by non-nucleoside reverse transcriptase inhibitors and protease inhibitors (17.8 [13.3-21.8] vs 16.6 [10.5-22.9] vs 16 [12, 18.7] ng/mL, respectively, P = .006). Sensitivity analyses confirmed the robustness of the associations between serum asprosin levels and MS across different subgroups. Serum asprosin levels are significantly higher in PLWH with MS than those without. Additionally, the use of integrase strand transfer inhibitors was strongly associated with elevated serum asprosin levels. These findings provide novel clinical insights into the role of asprosin in the pathogenesis of MS in PLWH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.